Navigation Links
High Growth Potential for Carotid Stent and Thoracic Aortic Stent Graft Markets

Procedural growth could increase by more than 20% over the next five years,

according to Millennium Research Group

WALTHAM, Mass., May 20 /PRNewswire/ -- According to Millennium Research Group's US Markets for Peripheral Vascular (PV) Devices 2008 report, the thoracic aortic stent graft market is poised to exceed 20% growth over the next five years. Carotid stents are another PV device segment with significant potential, although market expansion in this area is dependent on positive clinical trial data and expanded Centers for Medicare & Medicaid Services (CMS) reimbursement.

Treatment of thoracic aortic disease, a PV condition, is expected to witness a surge over the next five years as manufacturers focus on developing aortic stent grafts specific to this indication. The thoracic aorta is extremely risky to treat surgically because of the high mortality associated with this procedure; thus, the availability of a minimally invasive alternative -- thoracic endovascular aortic repair (TEVAR)-- has garnered a lot of attention among physicians and represents a significant opportunity for market expansion. Next-generation thoracic stent grafts, and clinical trials supporting their efficacy, will expand the treatable patient population, leading to growth in procedures in excess of 20% over the next five years.

Growth in carotid artery stenting procedures slowed to less than 5% per year in 2007 due to a lack of conclusive data supporting the safety and efficacy of the procedure compared to surgical alternatives. Compounding this lack was the CMS decision to not expand reimbursement coverage to include select asymptomatic carotid artery disease patients. In early 2008, CMS decided, however, to reexamine the expansion to reimbursement. If expanded reimbursement is approved, and the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) trial yields favorable results for stenting, carotid stenting growth could jump to greater than 20% before 2012.

"Our market forecasts present variable growth models," says Stephanie LaBelle, Analyst at Millennium Research Group. "These models consider the potential expansion of carotid stenting reimbursement, the completion of CREST, a large randomized clinical study comparing the efficacy of carotid artery stenting versus carotid endarterectomy, and the release of post-market carotid stenting surveillance data. These forecasts are supported by a survey of US physicians who rated expanded CMS reimbursement as the factor that would have the largest impact on growth in carotid stenting procedures; the release of clinical trial data supporting carotid artery stenting was rated second-most important."

The US Markets for Peripheral Vascular Devices 2008 report provides coverage of all key industry competitors, including Abbott Vascular, AngioDynamics, B. Braun, Boston Scientific, Cook Medical, Cordis, C. R. Bard, ev3, Medtronic, W. L. Gore, and Terumo, among others. Global coverage of this report includes Europe, Asia-Pacific, Latin America, Canada, and Japan.

About Millennium Research Group

Millennium Research Group (, a Decision Resources, Inc. company (, is the global authority on medical technology market intelligence and a leading provider of strategic information to the health care sector. Focused solely on the medical device, pharmaceutical, and biotechnology industries, the company provides its clients with the benefits of its specialized industry expertise through published reports and customized consulting services.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Amy Krohn

Millennium Research Group

416-364-7776 x101

SOURCE Millennium Research Group
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. OmniGuide(R) Secures $25 Million in Funding to Support Continued Growth and New Market Penetration
2. Diabetes Drugs Emerge as Top Force in Drug Spending Growth
3. Amil Has Strong Growth With High Profitability
4. Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year
5. New Data Shows Continued Growth of Long-Term Disability Claims and Decline in Social Security Disability Insurance Applications Approval Rate
6. PAREXEL International to Present at Robert W. Bairds 2008 Growth Stock Conference
7. Matrixx Initiatives, Inc. Announces Fiscal 2008 Revenue of $101 Million and Net Income Growth of 59% to $10.4 Million, or $1.04 Earnings Per Share Versus $0.66 in the Prior Year
8. Booth Joins PrePak Systems for Growth, Expansion
9. Neurotechnology Industry Reports Record Global Growth of $130.5 Billion in 2007
10. Some Weight-Loss Drugs Might Disrupt Brain Growth in Kids
11. Symposium Targets Critical Manufacturing Topics for Emerging Growth Companies
Post Your Comments:
(Date:12/1/2015)... , ... December 01, 2015 , ... ... 1980s we have seen vast improvements in scientific research and discoveries, leading us ... providing increased hope and relief to those affected by HIV/AIDS. Mediaplanet’s cross-platform edition ...
(Date:12/1/2015)... ... December 01, 2015 , ... The ... been lifted as IMAGE Information Systems launches MED-TAB™ -- the world’s first portable ... Meeting from November 29 to December 4, 2015. , MED-TAB is expected ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... must mark the film for accurate interpretation by the radiologist. The marking utensils ... inventor from Sacramento, Calif., has found a way to alleviate this problem. , ...
(Date:12/1/2015)... San Francisco, CA (PRWEB) , ... December 01, ... ... The Behavioral Health Center of Excellence (BHCOE) today announced that the organization has ... based in San Francisco, with a Distinguished Award. The award celebrates exceptional special ...
(Date:12/1/2015)... ... ... Lutronic, a leading innovator of aesthetic and medical laser and energy-based technology, ... in the United States. Clarity is a Superior Dual Wavelength Platform which combines ... single platform that is easy to own and operate. , For over a ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... -- CytRx Corporation (NASDAQ: CYTR ), a biopharmaceutical ... that it has reached its enrollment target of 400 ... trial of aldoxorubicin in patients with previously treated soft ... in Q1 2016. The Phase 3 trial is a randomized, ... from the FDA at 79 sites in ...
(Date:12/1/2015)... Dec. 1, 2015  InCarda Therapeutics, Inc. (InCarda), a ... of therapies for cardiovascular conditions via the inhalation route, ... in Australia . InCarda is planning ... Australia in the first half of ... medical centers in Adelaide and ...
(Date:12/1/2015)... , Dec. 1, 2015  Booth #3506 – Claymount is ... the annual meeting of the Radiological Society of ... this year. Based in the Netherlands ... Varian Medical Systems (NYSE: VAR ) and is one ... chambers and solid state automatic exposure control systems for controlling ...
Breaking Medicine Technology: